|
|
|
|
Vol. 59, Issue 4, 852-859, April 2001
Department of Cell and Neurobiology, School of Medicine (W.K.W., J.C.S.) and Department of Molecular Pharmacology and Toxicology, School of Pharmacy (K.C., J.C.S.), University of Southern California, Los Angeles, California
| |
Abstract |
|---|
|
|
|---|
The human monoamine oxidase (MAO) B plays a major role in the
degradation of biogenic and dietary amines such as phenylethylamine, benzylamine, dopamine, and tyramine. We previously showed that the
246/
99 MAO B promoter region exhibited the highest activity and
contained two clusters of overlapping Sp1 sites, a CACCC element and a
TATA box. Here, using a series of 10 deletion constructs of the
2-kilobase pair 5'-flanking sequence, we identified additional potential regulatory elements, including activator proteins 1 and 4, CAAT, GATA, upstream stimulatory factor (USF), estrogen receptor (ER),
and sex-determining region Y-box 5 (SOX5). Analysis of nine
site-directed mutations of
246/
99 region reveals that both clusters
of Sp1 sites contribute positively whereas the CACCC element
contributes negatively to the transcriptional activity. Gel shift
analysis demonstrates that in addition to Sp1, Sp3 can interact with
both clusters of Sp1 sites. Cotransfection experiments show that Sp1
and its closely related family member Sp4 can
trans-activate MAO B promoter activity through the
proximal cluster of Sp1 sites and its activation can be repressed by
the over-expression of Sp3 and a related family member BTEB2. These
results suggest that the binding to the overlapping Sp1 sites by
various members of Sp family is important for the regulation of the MAO
B gene expression.
| |
Introduction |
|---|
|
|
|---|
Monoamine
oxidase (MAO) metabolizes biogenic and dietary amines in the central
nervous system and peripheral tissues, and yields hydrogen peroxide
(H2O2). Two distinct MAOs
have been described: MAO A has higher affinity for serotonin,
norepinephrine, and inhibitor clorgyline; MAO B exhibits higher
affinity for phenylethylamine, benzylamine, and inhibitor deprenyl
[for review, see Shih et al., (1999)
]. In addition, MAO B converts
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to its toxic metabolite
1-methyl-4-phenylpyridine, which selectively destroys nigrostriatal
neurons (Gerlach et al., 1996
). The neurodegeneration induced by
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is similar to the neuronal
damage in Parkinson's disease and can be prevented by the MAO B
inhibitor deprenyl (Heikkila et al., 1984
).
Although both forms of MAO are expressed throughout the body, they
differ in cell- and tissue-specific and developmental expressions. Placenta and fibroblasts express predominantly MAO A (Egashira 1976
;
Edelstein and Breakefield, 1981
) and platelets and lymphocytes express
only MAO B (Bond and Cundall, 1977
; Donnelly and Murphy, 1977
).
Interestingly, in the brain, even though MAO A prefers serotonin and
MAO B prefers phenylethylamine as substrates, MAO A is predominantly
found in catecholaminergic neurons and MAO B is most abundant in
serotonergic neurons and astrocytes (Westlund et al., 1985
). Moreover,
MAO B, but not MAO A, activity increases progressively in the brain
throughout adult life (Fowler et al., 1980
). Aberrant increase of MAO B
activity in the elderly has been implicated in neurodegenerative
diseases such as Parkinson's disease (Schneider et al., 1981
),
Alzheimer's disease (Saura et al., 1994
), and Huntington's disease
(Mann et al., 1986
). On the other hand, low platelet MAO B activity has
been associated with several psychiatric disorders and behavioral
traits such as bipolar disorder, suicidal behavior, alcoholism (Oreland
1993
), poor impulse control [for review, see Holschneider and Shih
(1998)
] and smoking (Fowler et al., 1996
).
MAO A and MAO B genes are located on Xp11.2-11.4 (Lan et al., 1989
)
and consist of 15 exons with identical exon-intron organization (Grimsby et al., 1991
). The promoter organization of human MAO A and B
are different (Zhu et al., 1992
). The MAO A promoter shows bidirectional activity (Zhu et al., 1994
) and contains a functional polymorphism in the number of tandem repeat sequence (Sabol et al.,
1998
). However, the regulation of MAO B gene has not been addressed. In
the present study, we show that several potential cis-acting
regulatory elements are present within the 2 kilobases of 5'-flanking
sequence and the promoter region between
246 and
99 bp is critical
for the transcription of MAO B gene. The transcription factors Sp1 or
its closely related family member Sp4 can trans-activate the
promoter activity and its activation can be repressed by the over-expression of Sp3 or related family member BTEB2.
| |
Materials and Methods |
|---|
|
|
|---|
Cell Lines and Reagents. The 1242-MG (human astrocytoma) cell line was obtained from Dr. B. Westermark, and HeLa (human cervical adenocarcinoma) and HepG2 (human hepatocytoma) cell lines were purchased from the American Type Culture Collection (Manassas, VA). All three cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 mM HEPES, 2 mM L-glutamine, 100 U/ml penicillin, 10 µg/ml streptomycin, and 10% FBS (Life Technologies, Gaithersburg, MD). Polyclonal antisera against Sp1 and Sp3 were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Human MAO B Promoter-Luciferase Reporter Constructs.
The
BamHI/BamHI MAO B promoter fragment (
2099/
99
bp) was cloned into the polylinker site (BglII) upstream of
the luciferase gene (LUC) in the pGL2-Basic vector (Promega, Madison,
WI). The
2099/
99LUC was referred to wild-type (WT) promoter
construct in the deletion study. Serial deletion mutants (D1-D10) were
generated by restriction enzyme digestion using the
2099/
99LUC as a
template followed by Klenow fill-in and self-ligation. The following
restriction enzymes were used to generate the deletion mutant
constructs: XhoI/AspI (D1); XhoI/BglII
(D2); XhoI/SpeI (D3);
XhoI/ApaI (D4); XhoI/PstI
(D5); SpeI/HindIII (D6);
BglII/HindIII (D7); AspI/HindIII (D8);
BglII/SpeI (D9), and
NcoI/AspI (D10). The restriction enzymes PstI and HindIII were used to select positive
clones and to verify the correct orientation. One recombinant clone for
each of the constructs was chosen, and the plasmid DNA was extracted
and purified using Qiagen Miniprep kit (Qiagen, Inc., Chatsworth, CA)
following the manufacturer's instructions.
Site-Directed Mutagenesis of the Human MAO B Proximal Promoter
(
246/
99 bp).
Site-directed mutagenesis was used to mutate
potential transcription elements (Sp1, CACCC, and TATA elements) in the
proximal promoter region (
246 to
99). Mutant promoter constructs
(m1-m10) were generated using deletion construct D5 as a template.
Mutagenesis was carried out using the Amersham Mutagenesis kit
(Amersham Pharmacia Biotech, Piscataway, NJ) following the
manufacturer's instructions. The primers used for mutagenesis
(mutations underlined) were the following:
Transient Transfection and Luciferase Assay. Transfections in 1242-MG, HeLa, and HepG2 cells were performed using Superfect transfection reagent (Qiagen, Inc.) following the manufacturer's instructions. Exponentially growing cells were plated at a density of 5 × 105 cells/well in six-well plates (Costar, Cambridge, MA) with 2 ml of DMEM and 10% FBS, and grown until 80% confluent (24-36 h). For promoter deletion and mutagenesis studies, 2 µg of MAO B promoter constructs were cotransfected into the 1242-MG, HeLa, and HepG2 cells with 20 ng of plasmid pRL-TK (the herpes simplex virus thymidine kinase promoter fused upstream to the Renilla luciferase gene, which is used as an internal control; Promega). The plasmids were mixed with 100 µl of serum- and antibiotic-free medium and 10 µl of Superfect reagent. Following a 15-min incubation at room temperature, 600 µl of DMEM (with 10% FBS and antibiotics) were added to the DNA-Superfect complexes. The cells were washed once with phosphate-buffered saline and then incubated with DNA-Superfect complexes. After 2-h incubation, the cells were washed with phosphate-buffered saline and incubated with fresh DMEM (with 10% FBS and antibiotics). Cells were harvested 48 h later with Luciferase Assay lysis buffer (Promega). The cell lysates were then assayed for luciferase activity using the Promega Dual Luciferase Assay system (Promega). The expression plasmid pCMV-Sp1 was kindly provided by Dr. Robert Tjian, and the pCMV-Sp3 and pCMV-Sp4 were generous gifts from Dr. Guntram Suske. The cDNA sequence for BTEB2 has been described in GenBank (Accession no. AB030824). The expression plasmid pCMV-BTEB2 was generated by cloning BTEB2 cDNA into the polylinker sites of pCMV3.1 (Invitrogen, La Jolla, CA). For cotransfection experiments, the total amount of DNA for each transfection was kept constant by the addition of empty expression vector pCMV3.1.
Nuclear Protein Extraction and Gel Shift Assay. Cells were washed with cold phosphate-buffered saline, harvested by scraping, and pelleted. The cell pellets were then resuspended in 5 pellet-volumes of buffer A (10 mM KCl, 20 mM HEPES, 1 mM MgCl2, 0.5 mM DTT, and 0.5 mM phenylmethylsulfonyl fluoride), incubated on ice for 10 min, and centrifuged for 10 min. The pellets were resuspended in 3 pellet-volumes of buffer A plus 0.1% Nonidet P-40, incubated on ice for 10 min, and centrifuged for 10 min. The pellets were then resuspended in buffer B (10 mM HEPES, 400 mM NaCl, 0.1 mM EDTA, 1 mM MgCl2, 1 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, and 15% glycerol) and incubated on ice for 30 min with gentle shaking. Nuclear proteins were then centrifuged for 30 min and dialyzed for 4 h at 4°C against 1 liter of buffer D (20 mM HEPES, 200 mM KCl, 1 mM MgCl2, 0.1 mM EDTA, 1 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, and 15% glycerol). Protein extracts were cleared by centrifugation at 4°C for 15 min. Protein concentrations were determined by Bio-Rad protein assay (Bio-Rad, Hercules, CA).
The DNA fragment for gel shift assay was radiolabeled by Klenow fill-in. Labeled probes were purified by gel electrophoresis (5% polyacrylamide) and eluted in Tris/EDTA buffer. For DNA-protein binding, 5-µg nuclear extracts were diluted in binding buffer [40 mM HEPES, pH 8.0, 50 mM KCl, 1 mM dithiothreitol, 0.1 mM EDTA, 10% glycerol, 10 µg/ml of poly (dI-dC) (Sigma, St. Louis, MO)] with total volume of 20 µl. Antibodies against Sp1 or Sp3 were added (when required) and the mixture was incubated for 20 min at room temperature. Labeled probe (0.2 ng) was added to the mixture and incubated for additional 20 min at room temperature. The samples were then run on a 5% nondenaturing polyacrylamide gel in 1× Tris/borate/EDTA at 150 V for 3 h. Gels were dried and visualized by autoradiography.Statistical Analysis. All values were presented as means ± SEM. Student's t test was used for statistical analysis, and differences were considered significant when p < 0.05.
| |
Results |
|---|
|
|
|---|
Deletion Analysis of the Human MAO B Promoter.
To identify the
transcriptional elements regulating the transcription of MAO B gene,
the 5'-flanking sequence between
2099 and
99 bp (+1 was assigned to
the start of translation) was inserted into the promoter-less
luciferase reporter gene construct (pGL2-Basic). This clone was
isolated from the X chromosome-specific library (Zhu et al., 1992
). The
potential cis-acting regulatory elements are shown in Fig.
1A. A series of deletion constructs were
generated from the 5' or 3' end of the MAO B promoter as described
under Materials and Methods. Each of these deletion
constructs was transiently transfected into 1242-MG, HeLa, and HepG2
cells along with the pRL-TK plasmid to monitor transfection efficiency.
Both 1242-MG and HeLa cells have MAO A (0.35 and 0.44 nmol/20 min/mg of
protein, respectively) and MAO B (0.64 and 0.53 nmol/20 min/mg of
protein, respectively) activity but HepG2 cells show higher MAO A (6.46 nmol/20 min/mg of protein) and MAO B (8.2 nmol/20 min/mg of protein) activity. The WT MAO B promoter was constitutively active (Fig. 1B
legend) in all three cell lines studied, as shown in Fig. 1B. Deletion
of the region that contained GATA, AP-1, upstream stimulatory factor,
and estrogen receptor binding sites (D1) increased promoter activity by ~ 2-fold. Further deletion of two GATA binding sites (D2) increased MAO B promoter activity to ~ 3 folds, indicating that this region (
2099 to
1180 bp) contained silencer(s) that negatively regulate the transcription activity. However, further deletion of the AP-1, CAAT, and activator protein-4 sites (D3) decreased the promoter activity, suggesting that the region between
1180 and
868 bp contained enhancer element(s) that positively regulated the promoter activity. Deletion of the region that contains three AP-1 and one sex-determining region Y-box 5 binding sites (D4) increased promoter activity over 3-fold (compared with WT), indicating the presence of silencers in this region (
868 to
425 bp). Further deletion of the GATA and Sp-1 binding sites (D5,
425 to
246 bp) decreased the promoter activity.
|
868 to
425 bp and
1703 to
1313 bp) increased MAO B
promoter activity to ~2-fold, which was consistent with the results
obtained from D1 and D3, suggesting that these two regions may contain
silencer(s) negatively regulating MAO B promoter activity. Results from
the deletion study demonstrated that the MAO B promoter contained
multiple positive and negative regulatory elements, and the
transcription of MAO B gene depended on the cis-elements
within the proximal region (
246/
99 bp) of the promoter. This
proximal promoter contained two clusters (distal and proximal) of
overlapping Sp1 binding sites, a CACCC element and a TATA box. Our
previous results from primer extension experiments had shown that
multiple transcription initiation sites were present upstream of the
MAO B coding sequences (Zhu et al., 1992
150,
142,
139,
132,
128,
123,
119, and
117
(Zhu et al., 1992
150 were downstream
of the TATA box, suggesting that a TATA-dependent transcription was
present for the MAO B gene.
Distinct Functions of Sp1 Clusters, CACCC Element, and TATA Box in
the MAO B Promoter.
To define the cis-elements in the
proximal promoter (
246/
99 bp) that may contribute to MAO B gene
transcription, a series of mutant promoter constructs were generated
using the construct D5 (from the deletion experiment, Fig. 1B) as a
template. Mutations were introduced into each of the five Sp1 elements,
CACCC element, and TATA box (Fig. 2A).
Each of these mutant promoter constructs was transiently transfected
into HeLa, 1242-MG, and HepG2 cells along with the plasmid pRL-TK
(internal control to monitor transfection efficiency). The normalized
luciferase activity of the construct D5 (the WT promoter) was set to 1 and the fold induction of the mutant constructs were determined. As
shown in Fig. 2B, mutation of the first Sp1 element in the distal Sp1
cluster (m1) had no effect on MAO B promoter activity in HeLa and HepG2
cells but reduced ~50% promoter activity in 1242-MG cells. Mutation
of the second Sp1 element (m2) resulted in ~50% reduction in
promoter activity in HeLa and 1242-MG cells but ~40% increase in
promoter activity in HepG2 cells. When the distal Sp1 cluster was left intact, single mutations in the proximal Sp1 cluster (m7 and m8) resulted in a 40 to 80% reduction in promoter activity in all of these
cell lines. The promoter activity was also reduced when double
mutations were introduced into proximal Sp1 cluster (m4, m5, and m9).
Finally, when all three Sp1 elements in the proximal cluster were
mutated (m6), the MAO B promoter activity was reduced by ~80%. These
results indicated that the Sp1 elements in the proximal Sp1 cluster
were critical for the transcription of MAO B gene. In contrast, the
promoter activity was increased ~2.5 to 13-fold when the CACCC
element was mutated (m3, Fig. 2B), suggesting that the CACCC element
functioned as a negative regulatory element for MAO B promoter. A
significant reduction (~90%) in promoter activity was observed when
the TATA box was mutated (m10), indicating its functional role for the
transcription of MAO B gene. Results from the mutagenesis analysis of
the MAO B proximal promoter demonstrated that the Sp1 elements,
particularly in the proximal Sp1 cluster, contributed positively
whereas the CACCC element negatively to the MAO B promoter activity,
and the TATA box was critical for the basal transcription of the gene.
|
The Transcription Factors Sp1 and Sp3 Bind to the MAO B Proximal
Promoter (
246/
99 bp).
To determine whether nuclear proteins
may bind to the MAO B proximal promoter (
246/
99 bp; D5), nuclear
extracts from HepG2 cells were analyzed by gel shift assay using the
radiolabeled promoter fragment D5 as probe. As shown in Fig.
3A, five DNA-protein complexes (I, II,
III, IV, and V) were detected. To determine the specificity of the five
complexes, an excess of unlabeled promoter fragment was used as
competitor. The formation of all five complexes was abolished in the
presence of cold competitors, indicating that the complexes were
specific to the MAO B promoter (lane 2). Because the D5 promoter region
contains multiple Sp1 binding sites, these protein complexes may belong
to other members of Sp1 family. To further investigate the identities
of the proteins in the band shift complexes, supershift experiments
were performed using Sp1 and Sp3 antibodies. The complex II was
supershifted in the presence of Sp1 antibodies (lane 3), and complexes
I and III were supershifted by Sp3 antibodies (lane 4). The complexes I, II, and III were all supershifted when both Sp1 and Sp3 antibodies were present (lane 5). These results showed that the transcription factors Sp1 and Sp3 could specifically interact with the proximal MAO B
promoters. The two differently migrating bands of Sp3 may correspond to
the two Sp3 isoforms that arise from Sp3 mRNA via translational
initiation at two internal sites located within the
trans-activation domain (Kennett et al., 1997
). Although the internally initiated Sp3 could bind to Sp1 binding sites, it was shown
to be unable to stimulate the transcription of Sp-regulated genes
(Kennett et al., 1997
). The identities of complexes IV and V remained
to be determined, although their intensities were decreased by Sp1
antibodies, but not by Sp3 antibodies, suggesting that they may be
partially degraded Sp1 or Sp1-related protein.
|
Sp1 and Sp4, but not Sp3 and BTEB2, Are
trans-Activators of the Human MAO B Promoter.
To
determine whether members of the Sp family could modulate MAO B
promoter activity, the D5 promoter construct (
246/
99 bp) was
transiently transfected into 1242-MG cells with increasing amount
(10-1000 ng) of expression plasmids for Sp1, Sp3, Sp4, or BTEB2. As
shown in Fig. 4A, both Sp1 and Sp4
stimulated MAO B promoter activity in a dose-dependent manner, with Sp4
being the most potent trans-activator. In contrast, the
promoter activity was not affected by the over-expression of Sp3 or
BTEB2. These results indicated that although Sp1, Sp3, Sp4, and BTEB2
contain similar functional domains and can recognize the GC boxes, only Sp1 and Sp4 could trans-activate the MAO B promoter.
|
Identification of Transcriptional Elements Responsible for Sp1- and
Sp4-Mediated MAO B Promoter Activation.
The MAO B proximal
promoter contains five Sp1 binding sites and one CACCC element that
both Sp1 and Sp4 can recognize. To define the elements that were
responsible for the promoter activation mediated by Sp1 and Sp4, each
of the mutant MAO B promoter constructs (m2, m3, m6, and m7) was
transiently cotransfected into 1242-MG cells with expression plasmid
for Sp1 or Sp4. As shown in Fig. 5, no
significant change of Sp1- or Sp4-mediated activation was observed
(compared with WT) when the distal Sp1 cluster was mutated (m2).
Mutations of the proximal Sp1 (m6 and m7) resulted in ~80 to 90%
reduction in Sp1- or Sp4-mediated promoter activation. In contrast,
mutation of the CACCC element led to more than 3-fold enhancement of
Sp1 and Sp4-mediated promoter activations. These results indicated that
the proximal Sp1 cluster was largely responsible for Sp1- and
Sp4-mediated trans-activation of MAO B gene promoter. Furthermore, the CACCC element seemed to involve in both Sp1 and Sp4-mediated activation because its mutation enhanced the MAO B
promoter activation by Sp1 and Sp4.
|
| |
Discussion |
|---|
|
|
|---|
MAO B has been associated with a number of psychiatric disorders
and neurodegnerative diseases; therefore, it is important to understand
the molecular basis of its gene expression. In the present study, we
have identified several potential cis-elements in the 2 kilobases of 5'-flanking sequence of the MAO B gene. Moreover, we have
shown that the promoter region between nucleotides
246 and
99 was
sufficient to provide the basal promoter activity in the 1242 MG,
HepG2, and HeLa cells. This proximal promoter region (
246/
99)
contains multiple Sp1 consensus elements arranged into two clusters, a
negatively regulating element CACCC and a functional TATA box for the
transcription of MAO B gene. Although both Sp1 and Sp3 can interact
with both clusters of Sp1 elements, the proximal cluster was critical
for the binding of these factors because the mutation of this cluster
significantly affects their binding. Functional studies have
demonstrated that Sp1 and Sp4, but not Sp3 and BTEB2, can
trans-activate MAO B promoter activity. Furthermore,
over-expression of Sp3 or BTEB2 can repress the Sp1- or Sp4-mediated
promoter activation, possibly by competing with Sp1 and Sp4 for binding
to the overlapping Sp1 elements.
The transcription factors Sp1, Sp3, Sp4, and BTEB2 are members of the
Sp family encoding proteins with similar structural features and highly
conserved zinc finger DNA binding domain that can recognize the GC box
(GGGGCGGGC) and/or the GT motif (GGGTGTGGC) with similar affinities.
The Sp family was further divided into three subgroups based on the
structural relationships between the protein members: 1) the Sp
transcription factors; 2) the close relatives such as TIEG1 and TIEG2;
and 3) the kruppel-like factors such as BTEB2 and AP-2rep. Sp1, Sp3,
and Sp4 contain glutamine and serine/threonine-rich
trans-activation domains, whereas BTEB2 contains a
proline-rich trans-activation domain [for review, see Philipsen and Suske (1999)
]. The existence of proteins with
DNA-binding specificity similar to Sp1 indicates that gene regulation
by Sp1 is complex. Although Sp1 and Sp3 are expressed ubiquitously, Sp4 is predominantly expressed in the brain and BTEB2 is only expressed in
placenta and testis [for review, see Philipsen and Suske (1999)
]. Interestingly, the human MAO B is also highly expressed in the brain
(Westlund et al., 1985
) but not detected in the placenta (Egashira,
1976
). In the present study, we have demonstrated that the Sp1 and Sp4
are potent trans-activators of the MAO B promoter whereas
the Sp3 and BTEB2 repress the Sp1- or Sp4-mediated activation of the
promoter. Thus, it is tempting to speculate that the similar structural
but distinct functional and expression features of these Sp family
members may play an important role in the tissue-specific expression of
the human MAO B gene.
The human MAO B core promoter (
246/
99 bp) contains overlapping Sp1
sites that can be recognized by Sp1 and Sp3, and presumably by Sp4 and
BTEB2, based on their conserved DNA binding domains. Previous studies
have demonstrated that the binding of two adjacent Sp1 molecules to a
DNA sequence requires at least 10 bp between the central C of the two
Sp1 elements (GGGCGGG) (Gidoni et al., 1985
). Because the
Sp1 elements in the MAO B core promoter are overlapped, only one Sp1
can bind to each cluster of Sp1 binding sites at a time. On the other
hand, the activity and cellular content of Sp1 have been shown to be
regulated during development (Ammendola et al., 1992
), cellular
proliferation (Shin et al., 1992
), apoptosis (Piedrafita and Pfahl
1997
), and other cellular processes by post-translational modification
including phosphorylation (Jackson et al., 1990
) and glycosylation
through the O-linkage of the monosaccharide,
N-acetylglucosamine (O-GlcNAc) (Jackson and Tjian
1988
). Sp3 has been shown to act as a bifunctional regulator whose
activating or repressing activity is dependent upon both the promoter
and the cellular context (Majello et al., 1997
). Because only one of
these factors can bind to each cluster at one time, alterations of the
these factors and/or their DNA binding activities, and the competition
between these factors for binding to the same cluster may account in
part for the differential regulation of MAO B gene expression.
Mutation of the CACCC element (m3) activated the MAO B promoter
activity by ~2- to 13-fold (Fig. 2B) and enhanced Sp1- and Sp4-mediated promoter activations (Fig. 5), suggesting that the CACCC
element is a negative regulatory element. It is unclear at this time
whether other proteins might interact with the CACCC sequence motif.
Future experiments will be needed to determine the mechanism for this
negative regulation. The
246/
99 region contains two clusters of
overlapping Sp1 elements that contribute positively to the MAO B
transcription. The transcription factors Sp1 and Sp3 can interact with
both clusters of overlapping Sp1 sites. Furthermore, Sp1 and Sp4 can
trans-activate MAO B promoter activity via the overlapping
Sp1 sites and the promoter activations can be repressed by the
over-expression of Sp3 or BTEB2. The arrangement of overlapping Sp1
sites in the promoter suggests a complexity of transcriptional
regulation of MAO B gene. A number of promoters have been shown to
contain overlapping Sp1 sites in their proximal regions including
platelet-derived growth factor A-chain (Khachigian et al., 1995
) and
acetylcholinesterase (Mutero et al., 1995
). Redundant Sp1 binding site
had been shown to block epigenetic gene inactivation in the mouse aprt
gene promoter (Mummaneni et al., 1998
). It is unclear at this point why
the MAO B core promoter contains such arrangement of overlapping Sp1
sites. Future experiments will be needed to elucidate the function of
overlapping Sp1 elements in the MAO B core promoter.
In summary, we have identified both positive and negative regulatory elements in the proximal promoter of human MAO B gene. We have also demonstrated the importance of the cis-elements within the proximal promoter region in the regulation of MAO B gene. Moreover, we have shown that Sp1 and Sp3 could bind to either proximal or distal clusters of Sp1 sites in the proximal region of MAO B promoter. Overexpression of Sp1 or Sp4 activated MAO B promoter activity and its activation could be repressed by over-expression of Sp3 or BTEB2. This study provides novel information on how the MAO B gene is regulated. Given the importance of the members of Sp1 family in the MAO B gene regulation, it will be of interest to determine whether any of these factors is aberrantly expressed in the MAO B-related psychiatric disorders and behavioral traits as well as neurodegenerative diseases. A further understanding of the molecular basis of MAO B regulation will provide insights into the pathophysiology of these disorders and diseases and may ultimately lead to design of new therapeutics.
| |
Acknowledgments |
|---|
We thank Dr. Robert Tjian for providing us the Sp1 expression plasmid and Dr. Guntram Suske for the Sp3 and Sp4 expression plasmids.
| |
Footnotes |
|---|
Received August 29, 2000; Accepted January 4, 2001
This work was supported by National Institutes of Mental Health Grants R01-MH37020, R37-MH39085 (MERIT Award), K05-MH00796 (Research Scientist Award), and the Welin Professorship.
Send reprint requests to: Prof. Jean C. Shih, Department of Molecular Pharmacology and Toxicology, School of Pharmacy, University of Southern California, 1985 Zonal Avenue, PSC 528, Los Angeles, California 90033. E-mail: jcshih{at}usc.edu
| |
Abbreviations |
|---|
MAO, monoamine oxidase; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; WT, wild-type; DTT, dithiothreitol; bp, base pair(s); AP-1, activator protein 1.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. B. Wu, K. Chen, X.-M. Ou, and J. C. Shih Retinoic Acid Activates Monoamine Oxidase B Promoter in Human Neuronal Cells J. Biol. Chem., June 19, 2009; 284(25): 16723 - 16735. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-M. Ou, K. Chen, and J. C. Shih Glucocorticoid and Androgen Activation of Monoamine Oxidase A Is Regulated Differently by R1 and Sp1 J. Biol. Chem., July 28, 2006; 281(30): 21512 - 21525. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zhang, K. Chen, J. C. Shih, and C. T. Teng Estrogen-Related Receptors-Stimulated Monoamine Oxidase B Promoter Activity Is Down-Regulated by Estrogen Receptors Mol. Endocrinol., July 1, 2006; 20(7): 1547 - 1561. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Chen, X.-M. Ou, G. Chen, S. H. Choi, and J. C. Shih R1, a Novel Repressor of the Human Monoamine Oxidase A J. Biol. Chem., March 25, 2005; 280(12): 11552 - 11559. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-M. Ou, K. Chen, and J. C. Shih Dual Functions of Transcription Factors, Transforming Growth Factor-{beta}-inducible Early Gene (TIEG)2 and Sp3, Are Mediated by CACCC Element and Sp1 Sites of Human Monoamine Oxidase (MAO) B Gene J. Biol. Chem., May 14, 2004; 279(20): 21021 - 21028. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. K. Wong, K. Chen, and J. C. Shih Decreased Methylation and Transcription Repressor Sp3 Up-regulated Human Monoamine Oxidase (MAO) B Expression during Caco-2 Differentiation J. Biol. Chem., September 19, 2003; 278(38): 36227 - 36235. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Chadjichristos, C. Ghayor, J.-F. Herrouin, L. Ala-Kokko, G. Suske, J.-P. Pujol, and P. Galera Down-regulation of Human Type II Collagen Gene Expression by Transforming Growth Factor-beta 1 (TGF-beta 1) in Articular Chondrocytes Involves SP3/SP1 Ratio J. Biol. Chem., November 8, 2002; 277(46): 43903 - 43917. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. K. Wong, X.-M. Ou, K. Chen, and J. C. Shih Activation of Human Monoamine Oxidase B Gene Expression by a Protein Kinase C MAPK Signal Transduction Pathway Involves c-Jun and Egr-1 J. Biol. Chem., June 14, 2002; 277(25): 22222 - 22230. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||